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Abstract
Background: Apart from genetic alterations, development and progression of colorectal cancer
has been linked to influences from nutritional intake, hyperalimentation, and cellular metabolic
changes that may be the basis for new diagnostic and therapeutic approaches. However, in contrast
to genomics and proteomics, comprehensive metabolomic investigations of alterations in malignant
tumors have rarely been conducted.
Results: In this study we investigated a set of paired samples of normal colon tissue and colorectal
cancer tissue with gas-chromatography time-of-flight mass-spectrometry, which resulted in robust
detection of a total of 206 metabolites. Metabolic phenotypes of colon cancer and normal tissues
were different at a Bonferroni corrected significance level of p = 0.00170 and p = 0.00005 for the
first two components of an unsupervised PCA analysis. Subsequent supervised analysis found 82
metabolites to be significantly different at p < 0.01. Metabolites were connected to abnormalities
in metabolic pathways by a new approach that calculates the distance of each pair of metabolites
in the KEGG database interaction lattice. Intermediates of the TCA cycle and lipids were found
down-regulated in cancer, whereas urea cycle metabolites, purines, pyrimidines and amino acids
were generally found at higher levels compared to normal colon mucosa.
Conclusion: This study demonstrates that metabolic profiling facilitates biochemical phenotyping
of normal and neoplastic colon tissue at high significance levels and points to GC-TOF-based
metabolomics as a new method for molecular pathology investigations.
Background
Colorectal cancer is the third most common cancer for
both sexes, with an estimated number of 153760 new
cases and 52180 estimated deaths in the United States in
2007 [1]. Despite advances in diagnosis and surgical treat-
ment of colorectal cancer, incidence as well as mortality of
Published: 18 September 2008
Molecular Cancer 2008, 7:72 doi:10.1186/1476-4598-7-72
Received: 19 December 2007
Accepted: 18 September 2008
This article is available from: http://www.molecular-cancer.com/content/7/1/72
© 2008 Denkert et al; licensee BioMed Central Ltd. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.Molecular Cancer 2008, 7:72 http://www.molecular-cancer.com/content/7/1/72
Page 2 of 15
(page number not for citation purposes)
colorectal cancer has decreased only slightly in the last
twenty years. While the disease is curable in early stages,
the risk of recurrence and metastasis is substantially
higher for advanced tumors.
In addition to genetic alterations, the development of
colorectal cancer has been linked to a dysregulation of
energy homeostasis which is induced by hyperalimenta-
tion and adipositas as well as to influences from nutri-
tional intake [2-6]. Recently it has been suggested to use
this metabolic deregulation as the basis for new therapeu-
tic interventions [7].
While genetic alterations have been extensively character-
ized in colon cancer, the metabolic remodeling that
occurs downstream from genomic and proteomic altera-
tions have not been analyzed to a great extent, so far. This
is in part due to the fact that low molecular metabolites
are comparably difficult to analyze in a large-scale -omics
approach. Comparably new technologies allow compre-
hensive and quantitative investigation of a multitude of
different metabolites, which is called "metabolomics" in
analogy to the terms "transcriptomics" and "proteomics"
[8-10] currently, the analysis by gas chromatography (GC)
coupled with time-of flight (TOF) mass spectrometry is
used as a standard method for studying primary metabo-
lism [11-13]. While these methods are state-of-the-art in
the analysis of plant metabolism-, the translation to can-
cer research for the characterization of tumor types in
molecular pathology is still a challenge [14].
For cancer research, the ultimate aim is to define meta-
bolic profiles in normal, precancerous and cancerous tis-
sues and to link the dysregulation of tumor metabolism to
clinical outcome and treatment response. To reach this
aim, three steps are necessary. First, it is necessary to dem-
onstrate that metabolite levels can be determined in
human tissue samples that were collected during routine
surgical procedures. Second, it is necessary to identify as
many metabolites as possible, to go beyond a simple pat-
tern analysis towards an understanding of the functional
alterations of metabolism in tumor tissue. Third, we have
to develop tools that allow us to easily interpret metabolic
data by connection with the existing knowledge on meta-
bolic pathways that is described in databases such as the
Kyoto encyclopedia of genes and genomes (KEGG) data-
base [15].
In human samples, there may be general differences in
metabolism that are related to the genetic background or
– more likely – to the nutritional intake of the individuals
studied. It is therefore not clear, if the metabolic differ-
ences between tumor tissue and normal tissue are strong
enough to be detected despite the different genetic, meta-
bolic and nutritional background of individual patients.
Therefore, it was one aim of this study to investigate if a
set of paired samples of normal colon tissue and colorec-
tal cancer tissue from individual patients can be used for
metabolic profiling with GC-MS to detect and interpret
molecular changes in tumor tissue and to detect meta-
bolic patterns associated with different biological entities.
We evaluated different bioinformatical strategies to detect
those metabolites that are differentially expressed in nor-
mal tissue and cancer tissue. To facilitate the interpreta-
tion of the results with respect to changes in metabolic
pathways, we have developed a new method that projects
the metabolite interactions from the multidimensional
KEGG interaction lattice to a one-dimensional axis (PRO-
FILE). This method uses the relational information from
all metabolic pathways described in the KEGG database
but focuses on those metabolites and reactions that can be
observed in our investigation and thus builds the bridge
to functional interpretation of the metabolomic changes
in colon cancer.
Methods
Study Population and histopathological examination
For GC-TOF analysis 45 colon samples were examined at
the Institute of Pathology, Charité Hospital, Berlin, Ger-
many. The tissue specimens included 27 primary colon
carcinomas and 18 normal mucosa samples. For 15 cases
paired samples of cancer tissue and normal tissue were
available from the same patient. The tissues were dissected
by a senior pathologist in the operating room and was
immediately frozen in liquid nitrogen and stored at -
80°C. Additional H&E sections were performed for his-
topathological evaluation.
GC-TOF analysis
Fresh-frozen biopsy tissues (approximately 5 mg fresh
weight) were prepared by grinding in 2 ml Eppendorf
tubes for 30 s at 25 s-1 using 3 mm i.d. metal balls in a
MM300 ball mill (Retsch, Germany). Subsequent extrac-
tion was carried using 1 ml of a one phase mixture of chlo-
roform:methanol:water (2:5:2, v/v/v) at -20°C for 5 min.
Tubes were centrifuged for 30 s at 14,000 g and the super-
natant was collected and concentrated to complete dry-
ness. Samples were derivatized for GC-TOF analysis as
previously published [11]. In order to avoid cross-con-
tamination of samples, 1.5 μl of the derivatized solution
was injected in the split less mode into a thermodesorp-
tion unit (DTD, ATAS GL, Zoetermeer, Netherlands)
equipped with automatic exchange of liners and micro
inserts. The sample was introduced at 40°C using a pro-
grammable temperature vaporization OPTIC3 injector
(ATAS GL, Zoetermeer, Netherlands) and heated to
290°C using a 4°C/min ramp. Mass spectrometry analysis
was carried out using an Agilent 6890 gas chromatogra-
phy oven (Hewlett-Packard, Atlanta, GA, USA) which wasMolecular Cancer 2008, 7:72 http://www.molecular-cancer.com/content/7/1/72
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coupled to a Pegasus III time of flight (TOF) mass spec-
trometer from Leco (St Joseph, MI, USA). A MDN-35
fused silica capillary column of 30 m length, 0.32 mm I.D.
and 0.25 μm film thickness was used for separation using
a start temperature of 85°C which was ramped by 15°C/
min to 360°C. Mass spectra were acquired for a scan range
of 83–500 m/z and an acquisition rate of 20 spectra per
second. The ionization mode was electron impact at 70
eV. The temperature for the ion source was set to 250°C.
As an additional quality control we used stable isotope
labeled cholesterol as internal standard for lipophilic and
high boiling compounds for every sample as further con-
trol on analytical variation. The subsequent analysis of
quality control charts of this deuterated cholesterol stand-
ard did not show trends over the duration of data acquisi-
tion.
Data processing and normalization
Two stages of raw data processing were employed. In the
initial step, automated peak detection and mass spectral
deconvolution was performed by the Leco ChromaTOF
software (v2.32). For each sample, around 700 spectra
were exported with absolute intensities (peak heights).
These spectra were further processed by the in-house pro-
grammed database BinBase [16]. All known artifact peaks
such as internal standards, column bleed, plasticizers or
reagent peaks were excluded from the result sheets. The
algorithm underlying BinBase effectively removes incon-
sistent signals and noise peaks, yielding a total number of
206 metabolic signals that were reliably determined
across the entire sample set. Of these peaks, 107 were
structurally identified as known metabolites by compari-
son to mass spectra and retention indices of customized
reference mass spectral libraries that were acquired with
authentic standard compounds under identical data
acquisition parameters. For metabolites that were below
detection limits at a given sample, or for which mass spec-
tra did not match the quality criteria underlying the Bin-
Base algorithm, the data set resulted in missing values. In
order to minimize the number of such missing values,
only compounds were taken into account that were con-
sistently detected in at least 85% of samples. The metabo-
lite data were normalized relative to the sum of the 107
known metabolites in each sample and transformed to
the log scale keeping the missing values in the data set.
These missing values were further kept in the dataset for
metabolite-wise analyses (t-test, fold change calculation).
For collective analyses (PCA, clustering, classification) we
have replaced missing metabolite measurements by the
corresponding arithmetic means over all samples. The
entire data analysis was performed within programming
and visualization environment R [17]. In additional to the
normalization strategy described above, additional analy-
sis were performed using the raw (unnormalized) data as
input.
Principal component analysis (PCA)
Principal component analysis was performed using the
function prcomp() in the R package stats. In principal
component analysis the original set of metabolites is
reduced to a new set of principal components that retain
the variance-covariance structure of the data, but use
lesser dimensions of data space. Out of the 45 principal
components, the fist (PC1) as well as the second (PC2)
turned out be significantly different between colon carci-
nomas and normal mucosa (Welch's t-test, Bonferroni
corrected p-values). The values of the first two PCs were
plotted with designation of the cases as colon carcinoma
or normal mucosa. Further box plots served as visualisa-
tion of the discriminative power of the first and the sec-
ond PC.
Detection of metabolic changes
Alterations between colon carcinomas and normal
mucosa were evaluated by thresholds on the fold change
and Welch's t-test p-values. The results of three different
selection procedures (p < 0.05, p < 0.01, p < 0.00024)
were validated by repeated (n = 1000) random permuta-
tions of the samples. The false discovery rates (FDR) for
the corresponding metabolite lists were estimated as the
ratio (nexp/nobs) between the number of observed signifi-
cant metabolites between colon carcinomas and mucosa
tissues (nobs) and the number of metabolites that were
expected to be significant by chance from the permutation
distribution (nexp).
Prediction of the tissue type
Predictive models were derived in a two-step procedure
consisting of a feature selection step followed by the
proper construction of the classifier. We have applied the
nearest centroid classification (NCC) and compared it to
more complex methods like linear discriminant analysis
(LDA) and linear support vector machines (SVM). We
used an own implementation of the nearest centroid rule,
the implementation of LDA in the R package MAS and the
implementation of SVMs in the R package e1071. Feature
selection was performed by ranking according to the
result of Welch's t-test on the training set. The top 2, 3, ...,
206 metabolites were used as input for the construction of
the classifier and classification results were monitored in
dependence of the number of features. The classification
results were obtained in a leave-one-out approach and
reported separately the carcinomas and normal tissues.
Beyond that we have studied the stability of the classifica-
tion results under different choices of the training data. To
this end we have employed a protocol similar to that in
[28] and trained the classifier on balanced data sets of dif-
ferent size.Molecular Cancer 2008, 7:72 http://www.molecular-cancer.com/content/7/1/72
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Functional analysis of gene signatures by PROFILE 
clustering
Projection from interaction lattice is a new method for
the interpretation of metabolomic changes by the integra-
tion of pathway information. Based on the KEGG REAC-
TION data base [cf. ref. [15]] a metabolism network was
build by joining two compounds A and B with an edge
whenever there was a reaction that converted A into B.
Such reaction was assumed to exist if and only if A and B
where annotated as reaction pair with the qualifier "main"
in KEGG REACTION. The final network consisted of 4206
metabolites that were annotated as "main" in at least one
reaction pair. Based on these concepts, the bio-chemical
distance between two metabolites was defined as the min-
imal length of a joining path within the network. The
function johnson.all.pairs.sp() from the R package RBGL
was used to calculate the bio-chemical distance between
all pairs of the 4206 metabolites. The RBGL package is an
interface to the Boost C++ library for graph algorithms.
This result was useful for the interpretation of metabo-
lomic changes in colon tissue. Our study included 206
measurements of which 107 could be mapped to chemi-
cal compounds and metabolite names. Out of these com-
pounds, 84 were registered in the KEGG database and 71
were a main reaction partner in at least one of the reac-
tions annotated in KEGG REACTION. After projection to
these 71 metabolites, the network turned out to be com-
posed out of a single connection component, i.e. pair of
metabolites could be joined by a path inside the network.
Next we performed an agglomerative hierarchical cluster-
ing of these compounds with respect to the bio-chemical
distance to project the complexity of the metabolomic
network to an one-dimensional axis. In doing so the aver-
age linkage method was used to calculate distances
between clusters. Finally, the fold changes between cancer
and normal tissues were plotted against the functional
axis.
Results
Metabolic profiling of tissue samples by GC-TOF
We investigated a total of 45 samples. 27 of those samples
were from primary colon carcinomas, the 18 other sam-
ples were from normal colon mucosa. For 15 cases paired
samples of cancer tissue and normal tissue were available
from the same patient. The clinicopathological data is
shown in table 1. With gas chromatography-time of flight
mass spectrometry (GC-TOF), around 700 signals were
detected per sample using mass spectral deconvolution
software for peak detection. However, many of these sig-
nals were not consistently found in other samples or were
of too low abundance or too poor spectral quality to be
unambiguously assigned to unique metabolites. We have
hence utilized the novel in-house metabolomic database
BinBase that automatically filters out inconsistent signals
that cannot be annotate to known metabolites stored in
the database using an algorithm exploiting information
on retention index, mass spectral similarity and model
ions [16]. Moreover, this algorithm automatically adds
signals that were not included in the database if detected
peaks are consistently found in a relevant subset of sam-
ples. All metabolites were then compared against a library
of 620 reference spectra of known compounds that were
run on the same analytical system, yielding unambiguous
identification of metabolites in the database. The com-
plete list of metabolites detected is shown in the supple-
mental table 1 [see Additional file 1], comprising a total
of 206 metabolites that were consistently detected using
the BinBase algorithm outlined above under the addi-
tional constraint that peaks had to be positively identified
in at least 85% of all tissue samples. Metabolites from all
major pathways were detected, including TCA cycle inter-
mediates, purine and pyrimidine metabolism, lipids, sug-
ars, amino acids and others. Figure 1 gives examples of the
results of the GC-TOF mass spectrometry, demonstrating
differences between colon carcinoma and normal tissues.
Unsupervised evaluation of metabolite signatures using 
principal component analysis (PCA)
In a first step, we investigated the global metabolic differ-
ences in an unsupervised approach by using principal
Representative GC-TOF chromatograms of paired colon  carcinoma (thin line) and normal tissue (bold line) at  extracted ions m/z 218+100 between 530–610 s Figure 1
Representative GC-TOF chromatograms of paired 
colon carcinoma (thin line) and normal tissue (bold 
line) at extracted ions m/z 218+100 between 530–610 
s. Select mass spectra (m/z 80–300) are given for the signifi-
cantly different metabolites cysteine and phenylalanine, and 
the non-altered compound creatinine.
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component analysis (PCA). This approach was chosen
because supervised methods tend to over fit models if far
more variables than samples are present. In contrary,
unsupervised methods do not utilize clinical information
about the samples. PCA methods reduce the original set of
variables to a new set of principal components that retain
the variance-covariance structure of the data, but use
lesser dimensions of data space. We analyzed the PCA
results with Welch's t-statistics and found the first (PC1)
as well as the second (PC2) principle component signifi-
cantly different between cancer and normal tissue (Bon-
ferroni corrected p-values p = 0.0046 and p = 0.0002,
respectively). PC2 yielded a good, but not perfect separa-
tion of cancer from normal tissues (figure 2A). However,
a combination of PC2 with PC1 allowed a nearly perfect
linear separation with a single misassignment, as shown
in figure 2B and 2C. A single case of cancer tissue is
located in the normal tissue group. These good separation
results obtained with unbiased PCA indicate a high poten-
tial diagnostic value of metabolic profiles that reflect bio-
chemical differences between normal tissue and cancer
tissue.
Identification of differential metabolites by supervised 
analysis
In the next step we focused on the identification of those
metabolites that are differentially regulated between
malignant and normal tissue. For this aim, we used a
supervised approach based on the Welch t-test to investi-
gate the changes of metabolites in colon cancer tissue in
comparison to normal colon mucosa. Using a threshold
p-value of p < 0.01, a total of 82 metabolites with signifi-
cant differences were detected. 25 of these metabolites
were up-regulated in cancer tissue, while 57 were down-
regulated (figure 3). The complete list of metabolites with
fold changes and p-values is given in the supplemental
table 2 [see Additional file 1]. The large number of varia-
bles measured simultaneously in -omics studies gives rise
to a massive multiple testing situation with an accumulat-
ing risk of false positive detections. We have addressed
these issues in a two-step approach. First, we used the
stringent Bonferroni correction. 24 of the metabolites
were significantly different even after Bonferroni correc-
tion (p < 0.00024, figure 3, dark columns). To investigate
the influence of the normalization strategy on the result-
ing differential metabolites, we have performed an addi-
tional analysis using the raw (unnormalized) data as
input. Out of the 24 highly significant metabolites 14
(58%) could be confirmed at the high (p < 0.00024) and
Table 1: Clinicopathological characteristics of the study cohort
Characteristic Number of cases (%)
Tissue type
Normal colon tissue 18 (40%)
Colon carcinoma 27 (60%)
Cases with paired normal and carcinoma tissue 15 (33%)
Characteristics of colon carcinomas
pT stage
pT1 1 (4%)
pT2 4 (15%)
pT3 20 (74%)
pT4 2 (7%)
pN stage
pN0 12 (44%)
pN1 7 (26%)
pN2 8 (30%)
pM
pMX 26 (96%)
pM1 1 (4%)
DUKES Stage
A3  ( 1 1 % )
B9  ( 3 3 % )
C1 4  ( 5 2 % )
D1  ( 4 % )
Sex
male 12 (44%)
female 15 (56%)
Histological type
Adenocarcinoma 30 (100%)Molecular Cancer 2008, 7:72 http://www.molecular-cancer.com/content/7/1/72
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Principal component analysis (PCA) of colon cancer (dots) and normal colon tissues (circles) Figure 2
Principal component analysis (PCA) of colon cancer (dots) and normal colon tissues (circles). A linear combina-
tion of the first and the second principal component leads to a nearly perfect separation of carcinomas from normal tissues 
(A). A single misassigment is found: one tumor clusters within the normal tissue group. Box plots show the separation of can-
cer and normal tissues by the first and the second principal component (B, C). P-values shown are from Welch's t-test after 
Bonferroni correction for multiple testing. The boundaries of boxes and whiskers mark the 5th, 25th, 50th, 75th, and 95th percen-
tile.
A
B p=0.0046 p=0.0002 CMolecular Cancer 2008, 7:72 http://www.molecular-cancer.com/content/7/1/72
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Comparison of colon cancer versus normal tissue Figure 3
Comparison of colon cancer versus normal tissue. Fold change pattern of 82 significantly (p < 0.01) regulated metabo-
lites. p-values are given for each metabolite. Dark columns: metabolites that are highly significantly different even after Bonfer-
roni correction (p < 0.00024).
increased in normal tissue    |      increased in colon cancerMolecular Cancer 2008, 7:72 http://www.molecular-cancer.com/content/7/1/72
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19 (79%) at the normal (p < 0.05) significance level (fig-
ure 4). These findings suggest that the major metabolite
differences are not dependent on the normalization strat-
egy and exclude shifts of the effects between metabolites
during data normalization.
As an additional validation step, we used a permutation
analysis to estimate the number of false positives detected
by different p-value thresholds. After 1000 permutations
of the data set, the number of detected metabolites in all
of the shuffled data sets was lower than the number of reg-
ulated metabolites between cancer and normal tissues.
This was true for all investigated thresholds (p = 0.05, p =
0.01, and p = 0.00024). Finally, the false discovery rate
(FDR) and the number of false positive detections were
estimated from the permutation analysis, see table 2.
Only two false positives are expected within in the list of
82 metabolites that was generated by the threshold p =
0.01.
Cluster analysis
The results were visualized in a heatmap that was com-
bined with hierarchical clustering of samples and metab-
olites. Similarity assessment for clustering based on the
Pearson correlation coefficient and the average linkage
method. Clustering of tumor samples using the 82 signif-
icantly regulated metabolites resulted in a nearly perfect
separation of cancer tissue and normal tissue, with only
one carcinoma clustering in the normal tissue group (fig-
ure 5). This case of carcinoma is identical with the single
misassignment that has been observed by the unsuper-
vised principal component analysis. Unsupervised clus-
tering using all metabolites did not result in a complete
separation between carcinomas and normal tissue (data
not shown).
Classification models for prediction of tissue-type
Different supervised methods were employed in order to
construct predictive models that are capable of distin-
guishing between colon carcinoma and normal tissue
based on metabolomic profiling [18-20]. We used the
Evaluation of the influence of normalization Figure 4
Evaluation of the influence of normalization. Raw (unnormalized) data was used for comparison of differential metabo-
lites between normal colon and colon carcinoma. Of the 24 highly significant metabolites 14 (58%) could be confirmed at the 
high (p < 0.00024, **) and 19 (79%) at the normal (p < 0.05, *) significance level, indicating that the major metabolite differ-
ences are not dependent on the normalization strategy.Molecular Cancer 2008, 7:72 http://www.molecular-cancer.com/content/7/1/72
Page 9 of 15
(page number not for citation purposes)
nearest centroid rule for classification of normal tissue
versus carcinoma. This simple prediction rule classifies a
tissue according to its Euclidean distance to the average
mucosa and the average carcinoma signature; the pre-
dicted category is that with the smallest Euclidean dis-
tance. Nearest mean classification (NCC) was conducted
Table 2: Estimation of false discovery rate and the number of false positives for three different p-value thresholds. The estimates result 
from a permutation procedure that is detailed in the material and methods section.
p-value threshold number of detected metabolites False discovery rate (FDR) Estimated number of false positive metabolites
0.05 120 8.2% 10
0.01 82 2.3% 2
0.00024 24 0.2% 0
Supervised clustering of colon cancer tissue and normal colon mucosa with respect to 82 differentially regulated metabolites Figure 5
Supervised clustering of colon cancer tissue and normal colon mucosa with respect to 82 differentially regu-
lated metabolites. The heatmap visualizes the abundance of each of the metabolites in each of the samples ranging from high 
(red) over average (black) to low (green).Molecular Cancer 2008, 7:72 http://www.molecular-cancer.com/content/7/1/72
Page 10 of 15
(page number not for citation purposes)
for signatures containing 10, 25, 50, 100 and 206 metab-
olites and validated in a leave-one out approach. As
shown in table 3, for each classifier the sensitivity and the
specificity for detection of cancer was detected. All classi-
fiers had sensitivity and specificity around 95%. Classifi-
cation with more complex decision rules as linear
discriminant analysis (LDA) or support vector machines
(SVM) did not lead to an improvement of classification
accuracy (figure 6A–D). However, our results show that
metabolic profiling can be used to classify tissues and to
distinguish between normal and cancer tissue with high
accuracy. Classification results were robust with respect to
different choices of the training data set (figure 6E, F).
Interpretation of metabolic changes in tumor tissue using 
pathway information from the KEGG database (PROFILE)
Metabolic profiling analyses have the advantage that reli-
able and standardized information on metabolic path-
ways exists in the KEGG database. However, with the
current techniques in data acquisition and deconvolution
it is not possible to measure all the metabolites corre-
sponding to each pathway. Many compounds involved in
pathways are intermediates with too low concentrations
to be reliably detected. Others are involved in more than
one pathway, depending on the localization and distribu-
tion between the cellular compartments. KEGG can be
interpreted as a multidimensional metabolic network that
can be visualized by the KEGG pathway diagrams. How-
ever, these diagrams are only partially suitable for visuali-
zation and interpretation of metabolic results, since the
detected metabolites usually come from different path-
ways and not all metabolites from a single pathway can be
detected. Furthermore, the various cross-links between
different pathways that may be relevant as well are very
difficult to visualize with the conventional approach of
using full KEGG pathway maps. Efforts have been carried
out to reduce complexity by constructing static pathway
maps [21]; however, such approaches are not flexible
enough to integrate novel information and are too super-
ficial to depict the different roles and connections of
metabolites in metabolic networks. In previous reports
[22] we have proposed to exploit differences in metabolic
network graphs. On the one hand, such graphs are power-
ful because both identified and unidentified metabolic
signals can be taken into account. On the other hand, the
biological relevance and pathway connection of unknown
metabolites cannot be known. Therefore, we constrain
analyses here to only structurally identified compounds
that can be mapped to pathways.
We have developed a new approach to visualize metabo-
lomics data in context of the KEGG database. PROFILE is
based on projection of the metabolite interactions from
the multidimensional KEGG interaction lattice to a one-
dimensional axis. PROFILE starts with the calculation of
the metabolic distance of each pair of metabolites in the
KEGG interaction lattice. This first step is performed using
all metabolites in the KEGG database, without a restric-
tion to those that can be actually measured. Distances
between all metabolites are described as the number of
main biochemical reactions that are needed to connect
these metabolites. The result of this first step is a 4206 ×
4206 data matrix that represents metabolite distance
across the complete KEGG REACTION database. In a sub-
sequent step, this matrix is reduced to visualize relation-
ships between those metabolites that can actually be
measured by GC-TOF profiling of colon tissues.
Our study included 206 metabolic signals of which 107
could be identified by chemical structures and metabolite
names. Out of these compounds, 84 were registered in the
KEGG database and 71 were a main reaction partner in at
least one of the reactions annotated in KEGG REACTION.
In the next step these 71 metabolites were clustered with
respect to the distances derived from the KEGG REAC-
TION database. The resulting PROFILE clustering is
shown in figure 7 with links to the corresponding bio-
chemical pathways and key enzymes in supplemental
table 3 [Additional file 1]. As absolute concentrations of
different metabolites in human tissues can differ by orders
of magnitude, we found it especially useful to plot fold
changes between cancer and normal tissues along the
functional axis.
As shown in figure 7, the PROFILE method clusters many
compounds according to major metabolic pathways such
as urea cycle, purines or TCA cycle intermediates. Within
these pathways, compounds are usually deregulated in the
same direction, i.e. urea cycle intermediates, purines and
most amino acids up regulated in carcinoma tissues and
TCA cycle intermediates and free fatty acids down regu-
lated. Consequently, the clustering of results according to
metabolic distances helps annotating significant differ-
ences in regulation to pathways, in contrary to the alterna-
tive display of metabolic differences by p-values or by
fold-changes. Interestingly, the most significant metabolic
difference was found for up regulation of beta-alanine in
colon carcinoma.
Table 3: Sensitivity and specificity for the detection of colon 
cancer with the nearest centroid classifier based on the levels of 
10, 25, 50, 100 or 206 metabolites.
number of metabolites in the classifier sensitivity specificity
10 96% 94%
25 96% 89%
50 93% 94%
100 93% 100%
206 93% 94%Molecular Cancer 2008, 7:72 http://www.molecular-cancer.com/content/7/1/72
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Discussion
Our study demonstrates that large scale metabolic profil-
ing using GC-TOF mass spectrometry and database anno-
tation yields numerous significant differences between
colon carcinoma and normal colon mucosa. We have uti-
lized both unsupervised and supervised approaches to
investigate these metabolic differences. The metabolite
signatures are capable of predicting the status (normal tis-
sue or colon carcinoma) of a previously unknown test
tumor at sensitivity and specificity around 95%. Impor-
tantly, we could show that the classification results are
robust against different choices of the classificator and the
Validation of predictive models for the separation of colon cancer from normal tissues based on 2, 3, 4, ..., 206 metabolites Figure 6
Validation of predictive models for the separation of colon cancer from normal tissues based on 2, 3, 4, ..., 206 
metabolites. Sensitivity and specificity were calculated in a leave-one-out approach. A: nearest centroid classification (NCC), 
B: nearest mean classification (NMC), C: linear discriminant analysis (LDA), D: linear support vector machines (SVM). E/F: 
Validation of nearest centroid classification (NCC) with 206 metabolites by looking at training data sets with n = 6, 8, ..., 34 
samples. For each size n, 1000 training data sets were generated by randomly drawing n/2 tumors and n/2 normal tissues from 
the 45 samples. The remaining 45-n samples were used as test data. Sensitivity (E) and specificity (F) were reported and their 
distributions were visualized as box plots. The boundaries of boxes and whiskers mark the 5th, 25th, 50th, 75th, and 95th percen-
tile.
NCC
A
NMC
B
LDA
C
SVM
D
E FMolecular Cancer 2008, 7:72 http://www.molecular-cancer.com/content/7/1/72
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training set (figure 6). Regarding the extent of changes
detected, it is important to note that – from a tumorbio-
logical point of view – the comparison of normal tissue
and carcinoma tissue means that two completely different
entities are compared. Therefore we would expect that
comparison of those two tissue types leads to a large set of
completely different biomarkers. Similar results have
been reported in gene expression analysis. For example in
the study by Hlubek et al. [23] 39% of transcripts were dif-
ferentially expressed between colon tumor center and
colon normal tissue. Since metabolites are regarded as an
amplified output of a biological system, the expected
metabolite changes could be even more prominent com-
pared to genomics, as shown in our analysis.
Many of these metabolic events can be ascribed to known
metabolic dysregulation in cancer thus validating the
method itself. Metabolites involved in the citric acid cycle
were generally found at lower amounts in cancer tissues
compared to normal colon samples, in accordance with
results published earlier [24]. Purines were detected at
increased levels in malignant tissues as indicator for
higher capacity for DNA synthetic capacity. Similarly, we
found almost all amino acids to be up regulated in carci-
PROFILE analysis – comparison of metabolic differences between colon cancer and normal tissue clustered according to the  relational pathway information from the KEGG REACTION database Figure 7
PROFILE analysis – comparison of metabolic differences between colon cancer and normal tissue clustered 
according to the relational pathway information from the KEGG REACTION database. Significance of the meta-
bolic differences is designated by the stars behind the metabolite names: *** (high significance, p < 0.00024), ** (medium signif-
icance, p < 0.01), * (low significance, p < 0.05). The scale at the dendrogram refers to the number of main reactions in the 
KEGG database that link the metabolites to each other.Molecular Cancer 2008, 7:72 http://www.molecular-cancer.com/content/7/1/72
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noma tissues, which may be interpreted as reflecting cel-
lular needs for higher turnover of structural proteins. This
finding is in agreement with earlier publications for select
amino acids, notably glutamate and aspartate [25]. Simi-
larly, the high GABA contents had been described in colon
cancer tissues in a previous study [26]. Certain amino
acids are synthesized by mammalian metabolic routes,
often using TCA intermediates as precursor such as alpha-
ketoglutarate for glutamate and its derived amino acids,
and oxaloacetate for aspartate-derived amino acids. With
higher needs in amino acids but lower use of the TCA
cycle, an alternative route is needed to deliver carbon
backbones for such TCA-derived intermediates. Such
higher import may be accomplished by up regulation of
amino acid transporter, facilitating higher cellular needs
for energy metabolism as well as delivering carbon back-
bones for biosynthesis of cellular molecules. This inter-
pretation is supported by our finding of increased levels in
urea cycle intermediates in colon carcinoma tissues, indi-
cating higher turnover of amino acids. Interestingly, beta-
alanine was found as the most upregulated (f.c. = 4.9)
metabolite in carcinoma tissues with very high statistical
significance (p = 5.8e-13). In humans, beta-alanine is a
unidirectional catabolic product from aspartate in a decar-
boxylation reaction (EC:4.1.1.15) or by catabolic routes
from pyrimidine metabolism (EC:3.5.1.6). However, the
eventual fate of beta-alanine in humans is yet unclear,
since no enzymes are known that would transfer its back-
bone into acetyl-CoA or towards pantothenate metabo-
lism, as it occurs in other species. We therefore suggest
that beta-alanine might be important for metabolic alter-
ations in colon cancer. In addition, we found that not all
amino acids were up regulated in the same manner. In
fact, the glutamate/glutamine ratio was greatly altered in
comparison to normal colon tissue, indicating a lesser
role of aminotransferase reactions utilizing glutamine or
less need for transport of nitrogen across cells.
A limitation of this study was found in the need of nor-
malizing the raw data to the total sum of known metabo-
lites. The normalization strategy was developed in
analogy to gene expression studies and was chosen
because frozen tissue sections (as detailed in the methods
section) should not be weighed on fine balances in order
to preserve the cold chain and to prevent reactivation of
metabolism prior to extraction. We found that the raw
data for carcinoma tissues were significantly higher (p =
0.03) than those for normal tissue, relating to roughly a
33% increase in overall metabolic levels. However, this
might be due to either a higher number of tumor cells per
area of tissue or for generally enhanced metabolism. More
detailed studies would be needed to address this question.
In an additional validation using the raw (unnormalized)
data as input the major metabolic differences between
both tissue types could be detected, as well, suggesting
that the major metabolite differences are not dependent
on the normalization strategy.
The total time between surgery and freezing tissues was
kept as minimal as possible due to the fact that the frozen
section pathology laboratory was directly adjacent to the
operating room. Nevertheless, clinical and pathological
workflows do not allow for exact measures and timing of
tissue dissection parameters for samples collected during
routine surgical interventions. In addition, depending on
the surgical technique there is a variable amount of intra-
operative tissue ischemia due to surgical ligation of blood
vessels. This fact may account for the inability to quantify
glycolytic intermediates which have such a high turnover
in non-frozen tissues that these are found to be depleted
if metabolism is not immediately quenched after disrup-
tion of blood flow. To minimize unrelated technical noise
related to surgical procedures we have chosen to compare
tumor tissue and normal tissue collected during the same
surgery.
We have used a metabolomic approach by GC-TOF mass
spectrometry in order to gain a broad overview over pri-
mary metabolism at limited costs but at high sensitivity
and selectivity. In total more than 100 compounds could
be identified by chemical structure from as little as 5 mg
fresh tissue, which compares favorably to reports using
one dimensional 1H-NMR data acquisition. Specifically,
we here demonstrate for the first time the efficacy of an
automated annotation using a customized database
approach. On the one hand, the BinBase database unam-
biguously identifies chemically or biochemically known
compounds that are utilized for pathway mapping. On
the other hand, the database also facilitates adding novel
and potentially unique metabolic signals that yet are to be
structurally identified but that nevertheless were often
found to be differentially regulated at high significance
levels. These compounds are stored in the database by
unique identifiers combining mass spectra and retention
index information that enable re-using these database
entries for later studies aimed at validating initial biomar-
kers or at structural identification of these metabolic sig-
nals.
In the study presented here, we have focused on using
information from identified compounds by developing
and applying a new biochemical mapping method, PRO-
FILE. This method maximizes the interpretability of
results by facilitating physiological and biochemical
understanding of metabolic alterations in carcinoma. Spe-
cifically, PROFILE leads to simplified output of results
than mapping on single pathway maps from KEGG which
would focus on a small number of select metabolites
rather than taking into account the relative distances of
metabolites across the metabolic network.Molecular Cancer 2008, 7:72 http://www.molecular-cancer.com/content/7/1/72
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As a conclusion, our results show that metabolic signa-
tures as well as individual metabolites can be detected
from fresh-frozen tumor tissue of colon cancer and that
these alterations can be linked to relevant biochemical
pathways. Based on our results, we suggest that metabo-
lomics is a promising approach complementary to tran-
scriptomics and proteomics for analyses of changes in the
malignant phenotype. As metabolites constitute the
amplified output of a biological system, their quantitative
and qualitative analysis will be relevant for tumor biology
in different types of investigations. Databases such as the
one presented here will enable comparisons of findings
across studies and laboratories. Metabolomics can be used
for biochemical classification of different tumor types and
for comparison of malignant tumors with their corre-
sponding normal tissue. Recently, it has been suggested
that therapeutic approaches directed against metabolic
abnormalities may be useful in the treatment of malig-
nant tumors [27,28]. In this context, the metabolic profil-
ing approach described here may be useful to monitor the
complex changes in tumor metabolism that may occur
under these treatments. Furthermore, analysis of meta-
bolic alterations may be used as a new method for molec-
ular pathology to develop classifiers for therapy response
prediction, which may ultimately lead to the identifica-
tion of new prognostic markers. With the combination of
advanced instrumentation, standardized database algo-
rithms and the development of tools for interpretation of
data, our study provides a methodological basis for these
further investigations.
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